Evidence map›Paper›PMID 39465398›Full record

ArticleRheumatology international2024

Microfibrillar-associated protein 4 as a predictive biomarker of treatment response in patients with chronic inflammatory diseases initiating biologics: secondary analyses based on the prospective BELIEVE cohort study.

Bjørk K Sofíudóttir, Heidi L Munk, Robin Christensen, Sören Möller, Silja H Overgaard, Grith L Sorensen, Karen M Møllegaard, Jessica Pingel, Anders B Nexøe, Henning Glerup and 15 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Rheumatology international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Bjørk K SofíudóttirDepartment of Rheumatology, Odense University Hospital, Odense, Denmark. bks@rsyd.dk.ORCID 0000-0002-5918-3206
Heidi L MunkDepartment of Rheumatology, Odense University Hospital, Odense, Denmark.ORCID 0000-0002-2212-6283
Robin ChristensenResearch Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark.ORCID 0000-0002-6600-0631
Sören MöllerOPEN - Open Patient Data Explorative Network, Odense University Hospital, Odense, Denmark.ORCID 0000-0003-0858-4269
Silja H OvergaardSection for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.ORCID 0000-0001-6184-2154
Grith L SorensenDepartment of Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.ORCID 0000-0002-5273-1097
Karen M MøllegaardInternal Medicine Research, Unit University Hospital of Southern Denmark, Aabenraa, Denmark.ORCID 0000-0001-9940-0474
Jessica PingelInternal Medicine Research, Unit University Hospital of Southern Denmark, Aabenraa, Denmark.ORCID 0000-0002-9977-094X
Anders B NexøeDepartment of Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.ORCID 0000-0003-1674-9748
Henning GlerupUniversity Research Clinic for Innovative Patient Pathways, Silkeborg Regional Hospital, Silkeborg, Denmark.ORCID 0000-0002-8247-8766
Tanja GuldmannUniversity Research Clinic for Innovative Patient Pathways, Silkeborg Regional Hospital, Silkeborg, Denmark.
Natalia PedersenDepartment of Gastroenterology, Slagelse Hospital, Slagelse, Denmark.
Jens Frederik DahlerupDepartment of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0002-1587-7636
Christian L HvasDepartment of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0001-7973-7184
Karina W AndersenDepartment of Regional Health Research, University of Southern, Odense, Denmark.
Mohamad JawharaDepartment of Surgery, University Hospital of Southern Denmark, Aabenraa, Denmark.ORCID 0000-0002-0338-2548
Ole Haagen NielsenDepartment of Gastroenterology, Herlev Hospital, University of Copenhagen, Herlev, Denmark.ORCID 0000-0003-4612-8635
Fredrik Olof BergenheimThe Abdominal Center, Medical Section, Bispebjerg and Frederiksberg University Hospital, Copenhagen, Denmark.ORCID 0000-0001-6321-7715
Anette BygumDepartment of Clinical Research, University of Southern Denmark, Odense, Denmark.ORCID 0000-0002-3004-0180
Jesper R DavidsenDepartment of Clinical Research, University of Southern Denmark, Odense, Denmark.ORCID 0000-0003-4128-4014
Signe Bek SørensenInternal Medicine Research, Unit University Hospital of Southern Denmark, Aabenraa, Denmark.ORCID 0000-0003-3215-1236
Jacob B BrodersenDepartment of Regional Health Research, University of Southern, Odense, Denmark.ORCID 0000-0003-2530-7554
Jens KjeldsenDepartment of Medical Gastroenterology, Odense University Hospital, Odense, Denmark.ORCID 0000-0001-8148-6572
Vibeke AndersenInternal Medicine Research, Unit University Hospital of Southern Denmark, Aabenraa, Denmark.ORCID 0000-0002-0127-2863
Torkell EllingsenDepartment of Rheumatology, Odense University Hospital, Odense, Denmark.ORCID 0000-0003-0426-4962

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCurrently, there are no reliable biomarkers for predicting treatment response in chronic inflammatory diseases (CIDs).

objectiveTo determine whether serum microfibrillar-associated protein 4 (MFAP4) levels can predict the treatment response to biological therapy in patients with CIDs.

methodsThe BELIEVE study was originally designed as a prospective, multi-center cohort study of 233 patients with either rheumatoid arthritis, psoriatic arthritis, psoriasis, axial spondyloarthritis, Crohn's disease, or ulcerative colitis, initiating treatment with a biologic agent (or switching to another). Clinical assessment and blood sample collection were performed at baseline and 14-16 weeks after treatment initiation. The primary analyses included participants with available blood samples at baseline; missing data were handled as non-responders. The patients were stratified into the upper tertile of serum MFAP4 (High MFAP4) versus a combined category of middle and lower tertiles (Other MFAP4). The primary outcome was the proportion of patients with clinical response to biologic therapy after 14-16 weeks.

results211 patients were included in the primary analysis population. The mean age was 43.7 (SD: 14.8) years, and 120 (59%) were female. Positive treatment response was observed in 41 (59%) and 69 (49%) for High MFAP4 and Other MFAP4, respectively. When adjusting for pre-specified variables (CID, age, sex, smoking status, and BMI), the adjusted OR was 2.28 (95% CI: 1.07 to 4.85) for a positive treatment outcome in the High MFAP4 group.

conclusionA high MFAP4 status before initiating biological treatment is associated with a positive clinical response, when adjusting for confounding factors.

Indexed as

Biological ProductsBiomarkersAdultCarrier ProteinsChronic DiseaseExtracellular Matrix ProteinsFemaleGlycoproteinsHumansMaleMiddle AgedPredictive Value of TestsProspective StudiesTreatment OutcomeBiological ProductsBiomarkersCarrier ProteinsExtracellular Matrix ProteinsGlycoproteinsMFAP4 protein, humanAxial spondyloarthritisBiologic treatmentChronic inflammatory diseaseCrohn’s diseaseMFAP4PsoriasisPsoriatic arthritisRheumatoid arthritisTreatment responseUlcerative colitis

Identifiers

PMID39465398
PMCPMC11618207

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.